Four New Patents Issued, PROCYSBI® Granted Additional U.S. Orphan Exclusivity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Citi Upgrades Raptor Pharmaceuticals (RPTP) to Buy
January 26, 2016 5:46 PM ESTCiti upgraded Raptor Pharmaceuticals (NASDAQ: RPTP) from Neutral to Buy.
For an analyst ratings summary and ratings history on Raptor Pharmaceuticals click here. For more ratings news on Raptor Pharmaceuticals click here.
Shares of Raptor Pharmaceuticals closed at $3.83 yesterday.
... MoreRaptor Pharma (RPTP) Gains on New PROCYSBI Patents and Orphan Drug Exclusivity Extension
January 25, 2016 10:22 AM ESTRaptor Pharma (NASDAQ: RPTP) is gaining sharply after the company announced this morning that a U.S. PROCYSBI patent, number 9,233,077, is now... More
